Previous 10 | Next 10 |
Fifth Phase II trial of UV1 in cancer, and largest disease category to date UV1 will be investigated in combination with the standard-of-care pembrolizumab Expected data read-out by end of 2024 OSLO, Norway, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Ultimovacs ASA ("Ultimovacs") (...
UV1 as add-on therapy to checkpoint inhibitors awarded Fast Track designation Provides for potentially expedited review of UV1 Ultimovacs to host webcast at 13.00 CET Thursday, 21 October 2021 OSLO, Norway, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Ultimovacs ASA ("Ultimovacs") (O...
OSLO, Norway, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced continuing positive topline results in its ongoing U.S.-based Phase I clinical trial evaluating the Company's universal canc...
First patient in second cohort dosed with 400 μg of TET vaccine DSMB found no safety concerns for first cohort of three patients at 40 μg dose OSLO, Norway, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in imm...
OSLO, Norway, Aug. 20, 2021 (GLOBE NEWSWIRE) -- Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its second quarter 2021 results today. A presentation by the Company's management team will take place today on a webcast at...
Cohort 2 showed 60% objective response rate, 30% complete response rate 90% overall survival rate at 12 months follow-up Cohort 2 results reinforce results seen in cohort 1 Good safety and tolerability profile supports use of UV1 in combination treatments OSLO, Norway,...
OSLO, Norway, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, invites to a webcast presentation of its second quarter 2021 results on Friday 20 August 2021. The presentation ca...
Study will assess the benefit of combining UV1 with standard of care pembrolizumab Topline data expected in 2023 OSLO, Norway, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announc...
OSLO, Norway, July 05, 2021 (GLOBE NEWSWIRE) -- Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced the publication of a review of telomerase-based therapeutic cancer vaccines including the Company’s universal c...
UV1/pembrolizumab results in 30% complete responses plus 30% partial responses Good safety and tolerability profile supports expanded Phase II combination program Data highlighted at ASCO in poster presentation OSLO, Norway, June 04, 2021 (GLOBE NEWSWIRE) -- Ultimovacs A...
News, Short Squeeze, Breakout and More Instantly...
The Ultimate Software Group Inc. Company Name:
ULTI Stock Symbol:
NASDAQ Market:
Full recruitment of 154 patients with malignant melanoma in U.S. and Europe in 24 months Study provides randomized data on impact of UV1 on standard-of-care immunotherapy Topline progression-free survival data expected H1 2023 Oslo, 30 June 202 2 : ...
Oslo, 21. March 2022 : Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced that it will host a key opinion leader (KOL) webinar on the unmet need and treatment landscape of melanoma on Monday, March 28, 2...
Oslo, 1 7 February 202 2 : Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its fourth quarter 2021 results today. The presentation by the company's management team can be followed as a liv...